Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | SLC6A7 | Q99884 | 3/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222938 | 0.87 | CYP3A4 (0.55) | MEN1KMT2AHPGDMAPK1NAMPT | |
| SCHEMBL223301 | 0.86 | MEN1 (0.47) | MEN1KMT2ASLC6A7PTPN1POLB | |
| SCHEMBL224365 | 0.84 | ALDH1A1 (0.48) | MEN1KMT2ASLC6A7EPHX2NAMPT | |
| SCHEMBL225723 | 0.83 | ALDH1A1 (0.60) | MEN1KMT2ANAMPTMAPT | |
| SCHEMBL223262 | 0.82 | SMN1; SMN2 (0.47) | MEN1KMT2ASLC6A7PTPN1PRKAA2 | |
| SCHEMBL223162 | 0.81 | SMO (0.48) | MAPT | |
| SCHEMBL10182416 | 0.80 | ALDH1A1 (0.55) | MEN1KMT2APTPN1POLBMAPT | |
| SCHEMBL1221347 | 0.80 | KMT2A (0.62) | MEN1KMT2ASLC6A7HSD11B1PRKAA2 | |
| SCHEMBL224222 | 0.79 | ALDH1A1 (0.52) | MEN1KMT2APOLBMAPT | |
| SCHEMBL221711 | 0.79 | MAPT (0.61) | MEN1KMT2APOLBNAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-01-05 | — | — | US | claimed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | claimed |
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | claimed |
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-01-05 | — | — | US | disclosed |
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-01-05 | — | — | US | disclosed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | disclosed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | disclosed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | disclosed |
| EP-2307023-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009117659-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117659-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | MEN1 4883/4885KMT2A 1389/4885SLC6A7 1945/4885 |
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | MEN1 4883/4885KMT2A 1389/4885SLC6A7 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.